Table 2.
Patient characteristicsa
| Characteristics | All patients (n = 131) | Patients with an EI-ASM (n = 24) | Patients without an EI-ASM (n = 107) | p valueb |
|---|---|---|---|---|
| Female | 66 (50.4) | 9 (37.5) | 57 (53.3) | 0.242 |
| Age (years) | 80 (70–85) | 77 (64–83) | 80 (73–86) | 0.326 |
| Weight (kg) | 69 (58–80) | 70.7 (60–80) | 68 (58–80) | 0.783 |
| BMI | 25.2 (22–30) | 24 (20.75–31.25) | 25.4 (22.2–30) | 0.704 |
| Creatinine (mmol/L) | 90 (70–126) | 90 (73–114) | 89 (70–132) | 0.752 |
| DOAC | 1.000 | |||
| Apixaban | 111 (84.7) | 21 (87.5) | 90 (84.1) | |
| Rivaroxaban | 14 (10.7) | 2 (8.3) | 12 (11.2) | |
| Dabigatran | 6 (4.6) | 1 (4.2) | 5 (4.7) | |
| Indication | 0.327 | |||
| AF | 116 (88.5) | 20 (83.3) | 96 (89.7) | |
| VTE | 13 (9.9) | 3 (12.5) | 10 (9.3) | |
| Unknown | 2 (1.5) | 1 (4.2) | 1 (0.9) | |
| DOAC dosec | 0.354 | |||
| Standard dose | 48 (36.6) | 11 (45.8) | 37 (34.6) | |
| Reduced dose | 83 (63.4) | 13 (54.2) | 70 (65.4) | |
| Moderate CYP3A4 or P-gp inhibitors | 0.21 | |||
| Yes | 35 | 9 (37.5) | 26 (24.3) | |
| No | 96 | 15 (62.5) | 81 (75.7) |
Data are presented as n (%) or median (interquartile range)
AF atrial fibrillation, BMI body mass index, CYP cytochrome P450, DOAC direct oral anticoagulant, EI-ASM enzyme-inducing antiseizure medication, P-gp P-glycoprotein, VTE venous thromboembolism
aFor patients with more than one test, characteristics are presented for time of first DOAC measurement
bCalculated using Chi-squared and Fisher’s exact test for categorical measures and the Mann–Whitney U test for continuous measures
cDosing as per guidelines